News

Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical Development Program into the United States

Cyclarity Therapeutics, Inc., a clinical-stage biotechnology company developing cyclodextrin therapeutics to reverse atherosclerotic cardiovascular diseases and metabolic diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for UDP-003. UDP-003, designed by Cyclarity’s proprietary AI-enabled computational platform, is engineered to bind and extract oxidized cholesterol to restore cellular function and spur atherosclerotic plaque regression.

Latest news165

Paul Bresge of Ray Therapeutics

How a Promise Sparked Ray CEO Paul Bresge’s Quest to Treat a Blinding Disease

One of his daughters, Tamar, was diagnosed with retinitis pigmentosa in 2010 at the age of 15, when the family was living in Toronto. “We were basically told—in the whole span of . . . maybe two or three minutes—‘You’re going blind, there’s nothing that can be done to save your vision, here is a handbook to the Canadian National Institute for the Blind,’” he said. “That was a real pivotal moment for all of us, particularly her.” Read post
Four scientists from Replace Tx standing on a Bakar Labs balcony

With Funding in Hand, Tome Biosciences Buys Replace Therapeutics for $185M

Replace’s technology combines the site specificity of CRISPR/Cas9 technology with writing enzyme DNA ligase to manipulate small DNA sequences, a company press release stated, which complements Tome’s large DNA PGI technology. Per terms of the deal, Tome will acquire Replace for $65 million upfront and make other near-term milestone payments for a total deal value of up to $185 million through a mix of stock and cash. As a result, Replace will become a wholly-owned subsidiary of Tome. Read post
Tome Biosciences

Tome Biosciences Acquires Replace Therapeutics

Replace Therapeutics was founded by serial entrepreneur Shakked Halperin, PhD, whose previous company Rewrite Therapeutics was acquired by Intellia Therapeutics, and is backed by Civilization Ventures. The technology combines the site-specificity of CRISPR/Cas9 with the writing enzyme DNA ligase to precisely manipulate small DNA sequences. Read post
Umaro bacon

Umaro Is on C&E News’ Radar

There’s nothing quite like a crispy piece of bacon. But the pork industry releases more greenhouse gases than the entire country of Germany each year, according to the Food and Agriculture Organization of the United Nations. While some companies make plant-based bacon, the start-up Umaro Foods says existing products lack the key characteristic that makes bacon delicious: crispiness. Read post
Diver with kelp in ocean

Umaro, HOPO Win Joint ARPA-E Funding to Extract Rare Earth Elements from Seaweed

Umaro Foods will leverage advancements in HOPO Therapeutics' chelator technology to efficiently extract rare earth elements and platinum group metals from seaweeds. They will be applying advanced metal chelator molecules to selectively extract metals in a non-destructive manner from process streams producing valuable food-grade seaweed proteins and commodities such as agar, alginate, and carrageenan. Read post
Jenny Hamilton, Jennifer Doudna, and Navneet Matharu.

Navneet Matharu & Jenny Hamilton Win $2 Million in Seed Funding

Matharu, an Assistant Professor at UC San Francisco, is studying genetic disorders that have high unmet needs, and developing non-editing forms of CRISPR-based therapeutics. Matharu cofounded Regel Therapeutics, a Bakar Labs tenant, in 2021. “This is an extremely meaningful award from the HS Chau Foundation,” says Matharu.” This funding will enable us to utilize our foundational technology to diversify and expand the therapeutic development pipelines at Regel.” Read post
The ResVita Bio team (six scientists in the lab)

ResVita Bio Receives NIH Grant to Develop Breakthrough Treatment for Severe Atopic Dermatitis

"Within a year, we have been honored to receive two innovation grants from the NIH to develop therapies for both Netherton Syndrome, an orphan disease, and severe atopic dermatitis through our topical cell therapy approach," Dr. Zargar stated. "This is in addition to our Rare Pediatric Disease Designation for Netherton Syndrome from the FDA, setting the stage for the entry of our therapy into the clinic in 2025." Read post
Schematic DNA strand

Cystic Fibrosis Foundation Funds Nosis Bio to Design Gene Therapy Carriers

Gene therapy is usually delivered aboard a harmless virus that can be taken up by cells. However, the immune system may see the introduced gene or the viral carrier as foreign or unfamiliar and react to protect the body, causing an unwanted immune response. To make delivery safer, Nosis is using AI and deep learning — an AI technique that teaches computers to process data in a way similar to the human brain — to design new molecular carriers to get gene therapy directly into specific lung cells. Read post
Glyphic Biotechnologies, whose Co-founder Josh Yang is pictured, is moving forward with plans to expand into 31,000 square feet at Foundry31. Photo by Stan Olszewski

Glyphic Biotechnologies Launches Berkeley Expansion

The startup said in its business license application that the move to 3100 San Pablo would enhance Berkeley’s reputation as “a center for scientific innovation,” something the city has been working to cement over the last year or so. Berkeley City Councilmembers last fall signaled their unanimous interest in the Keep Innovation in Berkeley initiative, which outlined strategies to grow Berkeley’s biotech industry. Read post
Closeup of iris and pupil in eyeball

Ray Therapeutics Licenses Delivery Technology for Optogenetics Therapy

"Visual optogenetics is a disruptive technology which affords the opportunity to restore life-transforming levels of vision to blind and visually impaired patients with conditions such as retinitis pigmentosa,” said Paul Bresge, chief executive officer of Ray Therapeutics. “We have developed a next generation bioengineered optogenetic payload which we believe is optimized for human vision." Read post
BrightEdge's Farnaz Bakshi (center) presents Golden Ticket to Brad Niles, CEO of ARIZ (third from left) along with the BrightEdge and Bakar Labs teams

ARIZ and Catena Awarded Golden Tickets to Bakar Labs, Sponsored by ACS BrightEdge Fund

With the Golden Tickets, ARIZ and Catena each win one year of free office and lab space at Bakar Labs and access to BrightEdge’s robust network of resources to develop their cancer therapies. They will be able to access Berkeley campus resources, connect with Bakar Labs' business affiliates, and network with more than 30 fellow tenant companies. The combination of support from Bakar Labs and BrightEdge will, most importantly, allow ARIZ and Catena to bring their technology to patients sooner. Read post
Ben R. Taft

Via Nova’s Ben Taft on Challenges and Opportunities in Structure-Activity-Relationship Studies

Ben has been working as a medicinal chemist since 2011. After completing his postdoc, he joined Novartis, where he conducted discovery-phase research for oncology indications. While at Novartis, he transitioned to infectious disease drug discovery. He then joined Via Nova Therapeutics, a Novartis antiviral spinout founded by Don Ganem and Kelly Wong, when Novartis exited the infectious disease space. Read post